glp-1 receptor agonists effects on cardiovascular risk reduction Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction GLP-1 Agonists in Cardiovascular Diseases:

This exceptional result highlights its potential as one of the most effective anti-obesity therapies in development, underscoring the therapeutic promise of multi-receptor agonists in weight management

Acknowledgments This project was initiated by the Obesity Management Collaboration-UK (OMC-UK), which is a professional support network of healthcare professionals with an interest in obesity treatment

In a phase II trial, participants with obesity were randomly assigned to various doses of retatrutide from 14 , 8, or 12 mg or a placebo for 48 weeks [19]

Perhaps GLP-1 receptor agonists fit the bill as the long awaited holy grail for interventional weight loss

Understand the timeline